Fig. 2From: Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s diseasePatient disposition. BRZ, brazikumab; IV, intravenous; OL, open-label; PBO, placebo; SC, subcutaneousBack to article page